The present and the future of Peritoneal Dialysis

Hippokratia

Volumn 15, Issue SUPPL. 2, 2011, Pages 15-20

  Fourtounas, C ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Exit site infection; Hemodialysis; Icodextrin; Peritoneal dialysis; Peritonitis; Review

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BALANCED SALT SOLUTION; BICARBONATE; BUFFER; FLUCONAZOLE; GAMBROSOL TRIO; GENTAMICIN; GLUCOSE; HYPERTONIC SOLUTION; ICODEXTRIN; LACTIC ACID; NYSTATIN; PSEUDOMONIC ACID; SODIUM; UNCLASSIFIED DRUG;

ASSITED PERITONEAL DIALYSIS; AUTOMATED PERITONEAL DIALYSIS; AUTOMATION; HUMAN; INFECTION COMPLICATION; INFECTION PREVENTION; KIDNEY FAILURE; KIDNEY FUNCTION; MYCOSIS; PERITONEAL CATHETER; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONITIS; PRACTICE GUIDELINE; PREVALENCE; PSEUDOMONAS INFECTION; RENAL REPLACEMENT THERAPY; REVIEW; SKIN INFLAMMATION; STAPHYLOCOCCUS INFECTION;

EID: 83255166528     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Lameire N, Van Biesen W. Epidemiology of peritoneal dialysis: a story of believers and non believers. Nat Rev Nephrol. 2010; 6: 75-82.
2. Van Biesen W, Lamiere N, Vanholder R. Why less success of the peritoneal dialysis programs in Europe? Nephrol Dial Transplant. 2008; 23: 1478-1481.
3. Khawar O, Kalantar-Zadeh K, Lo WK, Johnson D, Mehrotra R. Is the declining use of long-term peritoneal dialysis justified by outcome data? Clin J Am Soc Nephrol. 2007; 2: 1317-1328.
4. Fourtounas C, Vlachojannis JG. PD underutilization in Europe: A call to action. Nephrol Dial Transplant. 2008; 23: 3365-3366.
5. Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1995; 6: 184-191.
6. The CANUSA study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol. 1996; 7: 198-207.
7. Vonesh EF, Moran J. Mortality in end-stage renal disease: a reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1999; 10: 354-365.
8. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002; 13: 1307-1320.
9. Mehrotra R, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med. 2011; 171: 110-118.
10. Garosi G, Oreopoulos DG. No need for an "expiry date" in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis. Int Urol Nephrol. 2009; 41: 903-907.
11. Oreopoulos DG, Coleman S, Doyle E. Reversing the decreasing peritoneal dialysis (PD) trend in Ontario: a government initiative to increase PD use in Ontario to 30% by 2010. Perit Dial Int. 2007; 27: 489-495.
12. Oreopoulos D, Thodis E, Paraskevas KI. The promising future of long-term peritoneal dialysis. Int Urol Nephrol. 2008; 40: 405-410.
13. Oreopoulos DG, Ossareh S, Thodis E. Peritoneal dialysis: past, present, and future. Iran J Kidney Dis. 2008; 2: 171-182.
14. Fourtounas C, Savidaki E, Dousdampanis P, Hardalias A, Kaliakmani P, Papachristou E, et al. Peritonitis during the first year after commencement of peritoneal dialysis has an impact on technique survival and patient morbidity. Adv Perit Dial. 2006; 22: 50-54.
15. Lo WK, Chan CY, Cheng SW, Poon JF, Chan DT, Cheng IK. A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kindey Dis. 1996; 28: 549-552.
16. Restrepo C, Chacon J, Manjarres G. Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial. Perit Dial Int. 2010; 30: 619-625.
17. Flanigan M, Gokal R. Peritoneal catheters and exit-site practice toward optimum peritoneal access: a review of current developments. Perit Dial Int. 2005; 25: 132-139.
18. Perakis K, Stylianou KG, Kyriazis JP, Mavroeidi VN, Katsipi IG, Vardaki EA, et al. Long-term complication rates and survival of peritoneal dialysis catheters: the role of percutaneous versus surgical placement. Sem Dial. 2009; 22: 569-575.
19. Henderson S, Brown E, Levy J. Safety and efficacy or percutaneous insertion of peritoneal dialysis catheters under sedation and local anesthesia. Nephrol Dial Transplant. 2009; 24: 3499-3504.
20. Asif A, Tawacol J, Khan T, Vieira CF, Byers P, Gadalean F, et al. Modification of the peritoneoscopic technique of peritoneal catheter insertion: experience of an interventional dialysis program. Semin Dial. 2004; 17: 171-173.
21. Zaman F. Peritoneal dialysis catheter placement by nephrologists. Perit Dial Int. 2008; 28: 138-141.
22. Asif A, Byers P, Gadalean F, Roth D. Peritoneal dialysis underutilization: the impact of n interventional nephrology peritoneal dialysis access program. Sem Dial. 2003; 16: 266-271.
23. Goh BL, Ganeshadeva YM, Chew SE, Dalimi MS. Does peritoneal dialysis catheter insertion by interventional nephrologists enhance peritoneal dialysis penetration? Sem Dial. 2008; 21: 561-566.
24. Dombros N, Dratwa M, Feriani M, Gokal R, Heimburger O, Krediet R, et al. European Best Practice Guidelines for peritoneal dialysis: Peritoneal Access. Nephrol Dial Transplant. 2005; 20(Suppl 9): S8-S12.
25. Li PK, Chow KM. Importance of peritoneal dialysis catheter insertion by nephrologists: practice makes perfect. Nephrol Dial Transplant. 2009; 24: 3274-3276.
26. Gokal R, Alexander S, Ash S, Chen DW, Danielson A, Holmes C, et al. Peritoneal catheters and exit site practice: toward optimum peritoneal access: 1998 update. Perit Dial Int. 1998; 18: 11-33.
27. Davies SJ. Preserving residual renal function in peritoneal dialysis: volume or biocompatibility? Nephrol Dial Transpl. 2009; 24: 2620-2622.
28. Perl J, Bargman JM. The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis. 2009; 53: 1068-1081.
29. Bargman JM, Thorpe KE, Churchill DN. CANUSA Peritoneal Dialysis Study Group Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001; 12: 2158-2162.
30. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int/ 2008; 73: 200-206.
31. Liakopoulos V, Dombros N. Patient selection for automated peritoneal dialysis: for whom, when? Perit Dial Int. 2009; 29(Suppl 2): S102-107.
32. Mehrotra R. Long-term outcomes in automated peritoneal dialysis: similar or better than in continuous ambulatory peritoneal dialysis? Perit Dial Int. 2009; 29(Suppl 2): S111-114.
33. Piraino B, Sheth H. Peritonitis - does peritoneal dialysis modality make a difference? Blood Purif. 2010; 29(2): 145-149.
34. Michels WM, Verduijn M, Grootendorst DC, le Cessie S, Boeschoten EW, Dekker FW, et al. Decline in Residual Renal Function in Automated Compared with Continuous Ambulatory Peritoneal Dialysis. Clin J Am Soc Nephrol. 2011; 6: 537-542.
35. Michels WM, van Dijk S, Verduijn M, le Cessie S, Boeschoten EW, Dekker FW, et al Quality of life in automated and continuous ambulatory peritoneal dialysis. Perit Dial Int. 2011; 31: 138-147.
36. Jager KJ, Korevaar JC, Dekker FW, et al. The effect of contraindications and patient preference on dialysis modality selection in ESRD patients in the Netherlands. Am J Kidney Dis. 2004; 43: 891-899.
37. Dimkovic N, Aggarwal V, Khan S, Chu M, Bargman J, Oreopoulos DG. Assisted peritoneal dialysis: what is it and who does it involve? Adv Perit Dial. 2009; 25: 165-70.
38. Povlsen JV, Ivarsen P. Assisted Automated Peritoneal Dialysis (AAPD) for the functionally dependent and elderly patient. Perit Dial Int. 2005; 25 (Suppl 3): S60-S63.
39. Lobbedez T, Moldovan R, Hurault de Ligny B, El Haggan W, Ryckelynck JP. Assisted peritoneal dialysis. Experience in a French renal department. Perit Dial Int. 2006; 26: 671-676.
40. Verger C, Duman M, Durand PY, Veniez G, Fabre E, Ryckelynck JP. Influence and type of home assistance on the prevention of peritonitis in assisted automated peritoneal dialysis patients. An analysis of data from the French Language Peritoneal Dialysis Registry. Nephrol Dial Transplant. 2007; 22: 1218-1223.
41. Brown EA, Dratwa M, Povlsen JV. Assisted peritoneal dialysis - an evolving dialysis modality. Nephrol Dial Transplant 2007; 22: 3091-3092.
42. Fourtounas C, Hardalias A, Dousdampanis P, Savidaki E, Vlachojannis JG. Intermittent Peritoneal Dialysis (IPD): An old but still effective modality for severely disabled ESRD patients. Nephrol Dial Transplant. 2009; 24: 3215-3218.
43. Davies SJ. Exploring new evidence of the clinical benefits of icodextrin solutions. Nephrol Dial Tranplant. 2006; 21(Suppl 2): 47-50.
44. Krediet RT. Effects of icodextrin on the peritoneal membrane. Nephrol Dial Transplant. 2010; 25: 1373-1375.
45. Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol. 2005; 16: 546-554.
46. Ventruroli D, Jeloka TK, Ersoy FF, Rippe B, Oreopoulos DG. The variability in ultrafiltration achieved with icodextrin, possibly explained. Perit Dial Int. 2009; 29: 415-421.
47. Chan TM, Yung S (2007) Studying the effects of new peritoneal dialysis solutions on the peritoneum. Perit Dial Int. 27(S2): S87-S93.
48. Gobin J, Fernando S, Santacroce S, Finkelstein FO. The utility of two daytime icodextrin exchanges to reduce dextrose exposure in automated peritoneal dialysis patients: a pilot study of nine patients. Blood Purif. 2008; 26: 279-283.
49. Sav T, Oymak O, Inanc MT, Dogan A, Tokgoz B, Utas C. Effects of twice-daily icodextrin administration on blood pressure and left ventricular mass in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int. 2009; 29: 443-449.
50. Dousdampanis P, Trigka K, Chu M, Khan S, Venturoli D, Oreopoulos D, et al. Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center's experience and review of the literature. Int Urol Nephrol. 2011; 43: 203-209.
51. Bargman JM. New technologies in peritoneal dialysis. Clin J Am Soc Nephrol. 2007; 2: 576-580.
52. McIntyre CW. Update on peritoneal dialysis solutions. Kidney Int. 2007; 71: 486-490.
53. Fourtounas C, Savidaki E, Dousdampanis P, Roumelioti M, Hardalias A, Kalliakmani P, et al. Acid-base profile and predictors of metabolic acidosis in patients undergoing peritoneal dialysis with lactate and bicarbonate buffered PD solutions. Adv Perit Dial. 2006; 22: 187-191.
54. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY et al. Superior patient survival for CAPD patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (BALANCE). Perit Dial Int. 2005; 25: 248-255.
55. Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR et al. Changing prescribing practice in CAPD patients in Korea: Increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant. 2006; 21: 2893-2899.
56. Rodríguez-Carmona A, Pérez Fontán M. Sodium removal in patients undergoing CAPD and automated peritoneal dialysis. Perit Dial Int. 2002; 22: 705-713.
57. Fourtounas C, Hardalias A, Dousdampanis P, Papachristopoulos V, Savidaki E, Vlachojannis JG. Sodium removal in Peritoneal Dialysis: The role of icodextrin and PD modalities. Adv Perit Dial. 2008; 24: 27-31.
58. Nakayama M, Kasai K, Imai H, TRM-280 Study Group. Novel low Na peritoneal dialysis solutions designed to optimize Na gap of effluent: kinetics of Na and water removal. Perit Dial Int. 2009; 29: 528-535.
59. Davies S, Carlsson O, Simonsen O, Johansson AC, Venturoli D, Ledebo I et al. The effects of low-sodium peritoneal dialysis fluids on blood pressure, thirst and volume status. Nephrol Dial Transplant. 2009; 24: 1609-1617.
60. Bargman JM, Krediet RT, Lo WK, Selgas R, del Peso G, Auxiliadora Bajo M, et al. What are the problems with using the peritoneal membrane for long-term dialysis? Semin Dial. 2008; 21: 11-23.
61. Trigka K, Dousdampanis P, Chu M, Khan S, Ahmad M, Bargman J, et al. Encapsulating peritoneal sclerosis: a single-center experience and review of the literature. Int Urol Nephrol. 201; 43: 519-529.
62. Balasubramaniam G, Brown EA, Davenport A, Cairns H, Cooper B, Fan SL, et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2009; 24: 3209-3215.
63. Burkart J. The future of peritoneal dialysis: PD in 2010 and beyond Dial & Transplant. 2010; 41: 349-353.